Clinical bottom line
Menopausal hormone therapy (MHT) remains a cornerstone for managing menopausal symptoms, particularly vasomotor symptoms and urogenital atrophy. Recent evidence suggests that MHT can be beneficial when initiated in early menopause for symptomatic women, with a favorable benefit-risk profile in this population. However, the decision to initiate MHT should be individualized, considering the patient's health status, risk factors, and personal preferences.
What the evidence shows
The Women's Health Initiative (WHI) study, a landmark trial, initially raised concerns about the risks of MHT, including increased risks of breast cancer, cardiovascular events, and thromboembolism [PMID: 12117397]. However, subsequent analyses and newer studies have refined our understanding of these risks, highlighting the importance of timing and duration of therapy.
A systematic review by Manson et al. (2017) found that the timing of MHT initiation is crucial, with women who start therapy closer to the onset of menopause experiencing more benefits and fewer risks compared to those who start later [PMID: 28492475]. This "timing hypothesis" suggests that early initiation of MHT may reduce coronary heart disease risk and improve overall mortality.
Recent guidelines from the North American Menopause Society (2022) recommend that MHT be considered for women under 60 years or within 10 years of menopause onset for relief of menopausal symptoms, provided they have no contraindications [PMID: 35476694].
Caveats and uncertainty
While MHT can effectively manage menopausal symptoms, it is not without risks. The potential for increased breast cancer risk remains a concern, particularly with prolonged use of combined estrogen-progestin therapy. The risk of thromboembolic events is also elevated, especially in older women or those with predisposing factors.
The variability in individual responses to MHT and the presence of comorbid conditions necessitate a personalized approach. The choice of hormone formulation, route of administration, and dosage should be tailored to the individual's risk profile and symptomatology.
Long-term data on the effects of MHT on cognitive function and dementia risk are still evolving, with some studies suggesting potential benefits, while others indicate no effect or increased risk. More research is needed to clarify these associations.
How this may change practice
The evolving evidence on MHT underscores the importance of individualized care in managing menopausal symptoms. Clinicians should engage in shared decision-making with patients, discussing the benefits and risks of MHT in the context of their health status and preferences.
The "timing hypothesis" may encourage earlier initiation of MHT in eligible women, potentially improving quality of life and reducing cardiovascular risks. As new formulations and delivery methods become available, they may offer additional options for tailoring therapy to individual needs.
Ongoing research and updated guidelines will continue to inform best practices, emphasizing the need for clinicians to stay current with the latest evidence to optimize patient outcomes.